ai+制药
在ai+制药领域，最新融资动态显示：Superluminal Medicines Inc完成B轮融资，投资方为BVF Partners、Gaingels、Cooley、Eli Lilly、Catalio Capital Management、NVIDIA、Insight Partners、RA Capital、Perceptive Advisors、Deep Track Capital。更多详细融资信息，可通过专题列表查阅。
2026-09-03
小分子创新药研发商
医药研发/制造
AI+制药
BVF Partners;
BVF Partners;
Gaingels;
Gaingels;
Cooley;
Eli Lilly;
Catalio Capital Management;
NVIDIA;
Insight Partners;
RA Capital;
Perceptive Advisors;
Deep Track Capital;
2026-08-19
疾病专用AI模型构建商
医药研发/制造
AI+制药
Blue Venture Fund;
Blue Venture Fund;
Breyer Capital;
Breyer Capital;
Founders Fund;
Thiel Bio;
Section 32;
2026-08-12
混合药物开发商
医药研发/制造
AI+制药
M Ventures;
M Ventures;
IT-Farm;
IT-Farm;
PsyMed Ventures;
97212 Ventures;
TechAviv;
Qumra Capital;
Vine Ventures;
2026-08-11
蛋白设计和免疫药物研发商
医药研发/制造
AI+制药
弘晖基金;
弘晖基金;
启明创投;
启明创投;
经纬创投;
纽尔利资本;
Granite Asia;
2026-08-11
空间药物发现外包服务商
医药研发/制造
AI+制药
Ministry of Economy and Innovation;
2026-08-10
AI制药与虚拟细胞创新技术研究商
医药研发/制造
AI+制药
千骥资本;
千骥资本;
顺禧基金;
顺禧基金;
中科创星;
鼎峰科创;
清科资本;
水木创投;
2026-08-04
AI临床试验模拟平台
医药研发/制造
AI+制药
Qumra Capital;
Qumra Capital;
Pitango;
Pitango;
Shoni Top Ventures;
Esplanade Ventures;
赛诺菲;
Bertelsmann Healthcare Investments;